<code id='B26AEDB98F'></code><style id='B26AEDB98F'></style>
    • <acronym id='B26AEDB98F'></acronym>
      <center id='B26AEDB98F'><center id='B26AEDB98F'><tfoot id='B26AEDB98F'></tfoot></center><abbr id='B26AEDB98F'><dir id='B26AEDB98F'><tfoot id='B26AEDB98F'></tfoot><noframes id='B26AEDB98F'>

    • <optgroup id='B26AEDB98F'><strike id='B26AEDB98F'><sup id='B26AEDB98F'></sup></strike><code id='B26AEDB98F'></code></optgroup>
        1. <b id='B26AEDB98F'><label id='B26AEDB98F'><select id='B26AEDB98F'><dt id='B26AEDB98F'><span id='B26AEDB98F'></span></dt></select></label></b><u id='B26AEDB98F'></u>
          <i id='B26AEDB98F'><strike id='B26AEDB98F'><tt id='B26AEDB98F'><pre id='B26AEDB98F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:explore    - browse:86953
          Alastair Grant/AP

          LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

          The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

          advertisement

          AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia